Related Experiment Video
Updated: May 22, 2025
Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
Published on: July 6, 2013
Establishment and application of a wild neonatal mouse model infected with an Echovirus 30 isolate
Ying Qu1,2, Jing Wang1,2, Yongbei Chen1,3
1Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.
Background:
Echovirus 30 (E30) is a significant pathogen associated with various illnesses such as viral meningitis, viral myocarditis. Currently, there are no specific drugs or vaccines targeting this virus. An appropriate animal model is imperative for assessing drug and vaccine efficacy.
Methods:
This investigation aimed to establish a neonatal mouse model using a clinical isolate E30/A538 and apply it to screen anti-E30 drugs. The study involved evaluating the susceptibility of different mouse strains to the isolate, determining the infectious dose, transmission route, and optimal age of the mice. This model was then used to assess antiviral efficacy.
Results:
Neonatal ICR mice infected intracranially with 5LD50 of E30/A538 at one-day-old displayed clinical symptoms such as tremors, lethargy, limb paralysis, and mortality. Importantly, the E30/A538-infected mice exhibited brain neuron apoptosis and severe myocardial necrolysis, closely resembling human infections. Elevated levels of viral RNA and positive antigen presence were predominantly detected in the brains and hearts of infected mice. Using this model to assess antiviral efficacy, it was demonstrated that interferon-α2a inhibited E30/A538 replication in vivo, mitigated histopathological changes in the brain, spinal cord, and myocardium, and enhanced the survival rate of neonatal mice.
Conclusions:
In summary, this research established a wild neonatal mouse model of E30/A538 isolate infection that mirrors the characteristics of human infection. The model demonstrated the efficacy of interferon-α2a in combating E30. This model would serve as a foundation for investigating the pathogenesis of E30, as well as for assessing the efficacy of vaccines and other antiviral treatments against E30.
Insights
A new mouse model effectively mimics Echovirus 30 (E30) infections in humans, showing promise for testing antiviral drugs like interferon-α2a against E30. This model aids in developing treatments for E30-related illnesses.
Area of Science:
- Virology
- Infectious Diseases
- Animal Models
Background:
- Echovirus 30 (E30) is a significant pathogen causing meningitis and myocarditis.
- No specific antiviral drugs or vaccines currently exist for E30.
- An effective animal model is crucial for evaluating potential treatments.
Purpose of the Study:
- To establish a neonatal mouse model for Echovirus 30 (E30) infection.
- To utilize this model for screening anti-E30 drugs.
- To investigate the pathogenesis and treatment of E30 infections.
Main Methods:
- A clinical E30 isolate (E30/A538) was used to infect neonatal ICR mice.
- Infectious dose, transmission, and optimal age were determined.
- The model was employed to assess the efficacy of interferon-α2a against E30.
Main Results:
- Neonatal mice infected with E30/A538 exhibited symptoms mirroring human E30 infections, including neurological and cardiac pathology.
- Viral RNA and antigen were detected in the brain and heart.
- Interferon-α2a treatment reduced viral replication, mitigated tissue damage, and improved survival rates.
Conclusions:
- A neonatal mouse model was successfully established, accurately reflecting human E30 infection.
- The model confirmed the antiviral efficacy of interferon-α2a against E30.
- This model provides a platform for future research on E30 pathogenesis and therapeutic development.
